In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other growth stocks to buy for the next 3 years. On April 29, Dan Ives of Wedbush Securities ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential.

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24 ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) traded down 4.2% during mid-day trading on Wednesday after Morgan Stanley lowered their price target on the stock from $1,146.00 to $1,124.00.

Please go ahead. Good morning. Thank you for joining us for Eli Lilly & Company's Q1 2025 earnings call. I'm Mike Czapar, Senior Vice President of Investor Relations. Joining me on today's call ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best long-term dividend stocks. Dividend stocks are increasingly popular with both every day ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug Wegovy gains steam in the obesity space. Wegovy was first to market but ...